AutoGenomics andGenomas Announce Strategic Partnership for the Development of DNA-GuidedDiagnostic Systems for the Treatment of Cardiovascular Disease, Obesity andDiabetes
Vista, CA and Hartford, CT, July 7, 2014 - AutoGenomics, Inc, a leader in automated microarray technology for molecular diagnostics, and Genomas, a biomedical company enabling DNA-guided medicine for personal healthcare, announced today that they have signed an agreement to jointly develop genetic tests and DNA-guided diagnostic systems for optimal selection of statins and for improved delivery of statin therapy for the treatment of cardiovascular disease, obesity and diabetes. This pioneering collaboration will provide clinicians and physicians with newly developed genetic tests and a decision support system which will allow them to manage statins, prescribe and dose these drugs on a DNA-guided, personalized basis to more effectively guide the therapy for each patient.
Statin drugs are the most prescribed medications in the world and are used to reduce the level of low-density lipoprotein cholesterol (LDL) in the blood. According to the Center for Disease Control and Prevention, there are currently more than 71 million American adults (over 20 years of age) with high LDL and it is estimated that over 43 million Americans are currently prescribed the statin class of cholesterol lowering drugs. However, statin LDL-lowering drugs can cause muscle aches, cramps and muscle weakness, and if not controlled, can lead to muscular injury. The newly developed DNA-guided statin diagnostic tests are designed to identify individuals who are genetically susceptible to muscle pain (myalgia) while on these statins and who may develop muscular injury (myopathy) while on high dose statin therapy.
Fareed Kureshy, President and CEO of AutoGenomics said “Our INFINITI® system in combination with Genomas’ SINM PhyzioType® System will provide a reliable, reproducible, cost-effective platform for clinical laboratories to provide results and guidance to physicians to optimize treatment strategies for lipid disorders.”
Gualberto Ruano, M.D., Ph.D., President of Genomas and Director of Genetics Research at Hartford Hospital said “The SINM PhyzioType® System combined with AutoGenomics’ INFINITI® multiplexing genetic test platform will enable cardiologists and clinicians to manage the variable lipid-altering efficacy and the risk of neuromuscular side effects that are prevalent in high-risk patients with heart disease and diabetes.”
Paul D. Thompson, M.D., Chief of Cardiology at the Henry Low Heart Center of Hartford Hospital commented: "Growing evidence indicates that genetics determines who develops muscle complaints with statins. The partnership will allow us to pursue the final implementation studies of the multi-gene biomarker system to personalize cardiovascular therapy.”
AutoGenomics Inc., a privately held company based in Vista, CA, designs, develops, manufactures and markets an automated, microarray-based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the areas of personalized medicine, women’s health, oncology, genetic disorders and infectious disease. With the discovery of genes and their link to various disease states, the AutoGenomics platform revolutionizes the way patients are diagnosed, monitored and managed, leading to a new and emerging era of personalized medicine and significant advances in drug selection and dosing. www.autogenomics.com
Genomas is a biomedical company delivering Personalized Medicine to modern clinical practice. The company develops revolutionary PhyzioType® Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease, and diabetes. PhyzioType® Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance. PhyzioType® Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted comparisons of side effect risk and efficacy among drugs for the individual patient. The company’s clinical pharmacogenetic tests and consultation service are provided through its Laboratory of Personalized Health (LPH), an accredited and licensed high-complexity molecular diagnostic center and its Personalized Health Portal (PHP), a medical informatics interface for clinician decision support. Genomas is located on the campus of Hartford Hospital in downtown Hartford, Connecticut.
For further information please contact:
Chief Executive Officer, AutoGenomics
760-477-2248 x 306